Following the December and January approvals of Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy, analysts believe another CRISPR drug approval is unlikely in the near future.
Following the December and January approvals of Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy, analysts believe another CRISPR drug approval is unlikely in the near future.